Recent Updates
Recently added Catalysts
RANI Neutral Sentiment Score: 60/100

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Key Takeaway: Rani Therapeutics Holdings, Inc. plans to report its financial results for the fourth quarter and full year ended December 31, 2024, on March 31, 2025. The management team will provide a business update during a conference call and webcast scheduled for 4:30 p.m. ET. The RaniPill® capsule, a proprietary platform technology, is designed to facilitate oral delivery of biologics and drugs, with prior successful clinical evaluations indicating its potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rani Therapeutics is advancing its novel RaniPill® capsule technology.
  • The company has successfully conducted several preclinical and clinical studies.
  • Upcoming financial results may indicate positive developments for the company.

Full Press Release Details

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Conference Call and Webcast
Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.ranitherapeutics.com. A webcast replay will be available in the investor relations section on the company’s website following the completion of the call.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Tags

Frequently Asked Questions

When will Rani Therapeutics release its financial results?

Rani Therapeutics will announce its financial results on March 31, 2025.

What time is the Rani Therapeutics conference call?

The conference call will start at 4:30 p.m. ET on March 31, 2025.

Where can I listen to the Rani Therapeutics conference call?

You can listen via the webcast link in the 'Investors' section of their website.

What is the RaniPill® capsule?

The RaniPill® capsule is a proprietary technology for oral delivery of biologics.

Does Rani Therapeutics conduct clinical studies?

Yes, Rani Therapeutics conducts preclinical and clinical studies to evaluate its technologies.

Last updated: Mar 25, 2025